Carbon dioxide/Perflubron

二氧化碳/潘氟隆

Report date: 2024/11/24 20:00:04

Base Information

Drug NameCarbon dioxide/Perflubron
Drug Alias Name全氟溴烷/二氧化碳Carbon dioxide+perfluorooctyl bromideCarbon dioxide and Perflubron二氧化碳•潘氟隆Carbon dioxide•Perflubron +[14] 
ClassificationSmall molecules
Mechanisms of ActionCell membrane permeability enhancers
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeBronchiectasis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsYes Perflubron
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSolaeromed Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSolaeromed Inc
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeBronchiectasis +[5] 

Other Information

ATC CodeN/A
Related LinksN/A